Novel cancer therapy
Explore Our Milestones in Biopharmaceutical Innovations
Discover the journey of our service in oncology pharmaceuticals. Since inception, we have focused on innovation and patient care, leading to groundbreaking advancements and expert solutions. Our legacy is built on trust, excellence, and a commitment to health.
Recurrent pancreatic cancer patient treated with Natural Killer Cell Therapy followed by an EGFR-targeted nanocell drug conjugate had prolonged survival of 38 months and continued survival at time of report. Click below to read the publication.
Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with EGFR-Targeted Nanocells Show Promising Outcomes and Minimal Toxicities
25 patients with end stage advanced pancreatic cancer were enrolled and received Engeneic. There was significant survival benefit, minimal side effects, and weight stabilization in patients with advanced pancreatic cancers.
10 Jun 2024- SAM Entered Global Partnership With EnGeneIC
Singapore Institute of Advanced Medicine Holdings Ltd. has entered into a strategic partnership with EnGeneIC Pty Limited (“EnGeneIC”), an Australia-based clinical-stage biopharmaceutical company.
24 Sep 2024-Engeneic Partners with Global CDMO Biocina to Advance Pioneering Cancer Treatment
Successfully launched a new treatment protocol enhancing patient outcomes significantly.
01 October 2024 -Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
EnGeneIC has appointed Professor Daniel Von Hoff to its Scientific Advisory Board to guide their metastatic pancreatic cancer trials. A renowned oncologist, Dr. Von Hoff brings expertise in cancer drug development and will advise on EnGeneIC's EDV™ nanocell technology, designed for targeted cancer treatment with minimal toxicity.
*Professor Daniel Von Hoff, M.D., F.A.C.P., FASCO, FAACR
Credits: Attachment (globenewswire.com)
